Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Markham

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Drugs|June 1, 1993
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomitingAnthony Markham, Eugene M Sorkin
Drugs|June 7, 2020
Selumetinib: First ApprovalAnthony Markham, Susan J Keam
Drugs|July 18, 2019
Camrelizumab: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|November 25, 2018
Omadacycline: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|August 26, 2019
Correction to: Camrelizumab: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|May 17, 2019
Peficitinib: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|August 18, 2018
Danoprevir: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|June 8, 2019
Sotagliflozin: First Global ApprovalAnthony Markham, Susan J Keam
European Journal of Pharmacology|August 23, 2002
Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2'-pyridylisatogen tosylate and related compoundsKevin Menton, Michael Spedding, Pierre Gressens, et al.
The European Journal of Neuroscience|February 1, 2012
Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathwaysAnthony Markham, Ian Cameron, Rasneer Bains, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Drugs|June 1, 1993
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomitingAnthony Markham, Eugene M Sorkin
Drugs|June 7, 2020
Selumetinib: First ApprovalAnthony Markham, Susan J Keam
Drugs|July 18, 2019
Camrelizumab: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|November 25, 2018
Omadacycline: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|August 26, 2019
Correction to: Camrelizumab: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|May 17, 2019
Peficitinib: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|August 18, 2018
Danoprevir: First Global ApprovalAnthony Markham, Susan J Keam
Drugs|June 8, 2019
Sotagliflozin: First Global ApprovalAnthony Markham, Susan J Keam
European Journal of Pharmacology|August 23, 2002
Role of spin trapping and P2Y receptor antagonism in the neuroprotective effects of 2,2'-pyridylisatogen tosylate and related compoundsKevin Menton, Michael Spedding, Pierre Gressens, et al.
The European Journal of Neuroscience|February 1, 2012
Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathwaysAnthony Markham, Ian Cameron, Rasneer Bains, et al.
Pageof 9